What is oncolytic immunotherapy?

Oncolytic immunotherapy uses viruses that have been modified to selectively replicate in and kill tumors.
These therapies are designed to fight cancer in two ways:

  1. Directly kill tumors at the site of injection
  2. Activate the immune system to kill cancer cells anywhere in the body


How is oncolytic immunotherapy administered?

Oncolytic immunotherapy is a tumor-directed therapy. That means that the immunotherapy is given as an intra-tumoral (IT) injection; injected directly into some or all of the tumors, depending on size and how many tumors are present.

Check out the videos below to learn more about how oncolytic immunotherapy is administered.

Administering an Oncolytic Immunotherapy to Patients with Superficial / Cutaneous / Nodal Tumors from Replimune on Vimeo.

Administering an Oncolytic Immunotherapy to a Deep Visceral Organ from Replimune on Vimeo.

Ongoing Clinical Trials

Clinical trials are the research studies intended to find out if a new treatment is safe and provides better outcomes than the existing standard of care–the best available known treatment. Our clinical programs are designed to evaluate the safety and effectiveness of our investigational therapies in a range of solid tumors as single agents and combination with other immunotherapies. Prior research has shown that oncolytic immunotherapy may be able to increase the effectiveness of some other cancer therapies by activating the immune system to fight cancer.

The safety of our patients is a top priority. We conduct our clinical trials with the highest possible standards.
Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety.

To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here.

You can find more information about our ongoing clinical trials below. If you are a patient and have questions about whether you are eligible for a clinical trial, please talk to your doctor.

To address serious unmet needs in patients that do not qualify for ongoing Replimune clinical trials, information regarding our Expanded Access Policy, can be found here.